Closed Loop Medicine has secured £250,000 from Innovate UK to support clinical evaluation of a drug + digital combination product for hypertension and COVID- 19 monitoring.
Babraham Research Campus
The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise. World class research and business come together to promote innovation and strengthen links between academia and the commercial world.
Telephone: +44 (0)1223 496 000
Address :
Babraham Bioscience Technologies Babraham Research Campus Babraham
Post Code: CB22 3AT
Country: United Kingdom
Website: http://www.babraham.com/
Membership Type: Cambridge University Department
Our mission is simple.
We will be the best place in Europe to start-up and scale-up a life science business. Our aim is to create an environment where companies can focus on developing their science and building their business in a supportive and highly networked community, helping to create new medicines, jobs and growth, and maximising the impact of UK science.
There are no Products & Services to display
Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.
16-06-2020
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge.
02-06-2020
Eisai joins AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the Babraham Research Campus bio-incubator programme, supporting early-stage science and new life science companies within the Cambridge cluster.
27-04-2020
A drug discovery business has announced that it will soon be able to complete 15,000 COVID-19 diagnostic tests per month in a bid to help the country combat the virus.
06-04-2020
Two start-up ventures share the inaugural LifeArc ‘Accelerate @Babraham Award'.
06-03-2020
PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.
02-03-2020
Babraham Investor Conference (BIC) is a must attend one-day conference for investors focusing on early-stage and scale-up life science and med-tech companies from across the UK and Europe.
03-02-2020
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie, a global, research-driven biopharmaceutical company, have announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration.
04-12-2019
Mundipharma joins AstraZeneca and LifeArc in providing funding for the continued development of the ‘Accelerate@Babraham’ initiative .
11-11-2019
LifeArc joins AstraZeneca in providing funding towards the continued development of the Babraham Research Campus’ Accelerate@Babraham initiative, which aims to nurture the development of early-stage science concepts and new life science companies.
23-09-2019
Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and will receive an extended programme of mentoring and support.
21-05-2019
Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has announced the appointment of Dr James Summers as an independent member to its Board of Directors, with immediate effect.
01-05-2019
PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital.
30-04-2019
Kadans enters the UK life science market by acquiring, from Imperial College ThinkSpace, the B900 building located on the Babraham Research Campus (BRC) in Cambridge, adding to its Pan-European science park portfolio.
09-04-2019
The world’s first validated prognostic test for inflammatory bowel disease (IBD) is now available via Cambridge University Hospitals NHS Foundation Trust’s Genomic Laboratory Hub.
02-04-2019
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
28-03-2019
Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
25-03-2019
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.
21-03-2019
Cambridge-based vaccine company ImmunoBiology Ltd (ImmBio) has entered a licensing agreement with the largest vaccine producer in China, CNBG, to co-develop ImmBio’s PnuBioVax Vaccine against pneumococcal infection.
19-03-2019
Pages
There are no events to display
There are no jobs to display
No Blog articles found
